secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2025-11-17T23:59:59+00:00
Accession:  0001193125-25-283873
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks announces positive Phase 3 results for Ziihera in first-line HER2+ GEA
--------------------------------------------------------------------------------

- Ziihera + chemo showed statistically significant PFS improvement vs trastuzumab + chemo; OS trend with further analysis expected mid-2026.
- Ziihera + Tevimbra (tislelizumab) + chemo showed statistically significant improvements in both OS and PFS vs control.
- PFS and OS benefit observed across PD-L1 positive and negative subgroups in the triple combo arm.
- Jazz plans to submit supplemental BLA in 1H-2026; Zymeworks eligible for milestones and royalties.
- Safety profile consistent with known safety of each agent; no new signals observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312525283873/0001193125-25-283873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312525283873/d17392d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-283873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer